Smart Phones & Tablet Usage in Pharma

Survey of over 5,400 specialists, PCPs on Physicians Consulting Network indicates 2/3 own smartphones, 1/4 have tablets

Amplify’d from www.knowledgenetworks.com

New York, NY; March 31, 2011: For pharmaceutical companies marketing to health care professionals, going mobile is only part of the story. New research by Knowledge Networks using the Physicians Consulting Network (PCN®) shows that doctors are seeking a combination of digital and in-person marketing. Specialists and PCPs alike are relying more and more on smartphones and tablets to check email, research medications and conditions, and take online surveys; but they still prefer in-person visits with drug sales reps over electronic pharma marketing (“e-detailing”) by a factor of three to one.

Drawing on responses from 5,490 doctors, the 2011 Digital MD Marketing research shows that

67% of PCPs and 61% of specialists now have a smartphone (64% of doctors overall) 27% of PCPs and specialists alike have tablet computers (such as iPads) – about 5 times the level in the general population Shopping and survey taking via mobile devices have grown significantly since 2010, but “e-detailing” grew less dramatically and is less common Reference applications, such as Epocrates and WebMD, are the most popular mobile medical “apps” – while apps from pharmaceutical manufacturers receive minimal use Read more at www.knowledgenetworks.com

 

See this Amp at http://bit.ly/hDtK24

Re-inventing the wheel- collaborative drug discovery

Traditional Model for pharmaceutical drug discovery, development and testing is being challenged on all sides. Strict regulatory reforms create a tougher review and approval process for pharma industry. Saving on development time and capital costs is what is to be achieved through collaborative partnerships.

Amplify’d from medhealth.tmcnet.com

Endo Pharmaceuticals Embraces Virtual R&D to Expand Drug Pipeline

MedHealthWorld interviewed Ivan Gergel, M.D. the Executive Vice President for Research and Development at Endo Pharmaceuticals to find out more about the Endo strategy for innovation and growth.

MHW: Could you explain how this virtual R&D model works in practice?

IG:  Our Virtual Discovery Program now combines in-house experts in multiple research fields with using the know-how of research partners in India and in other countries that have strong drug discovery development track records. Our in-house team provides the essential oversight and direction and using multiple remote research teams allows us to take “more shots on goal,” to increase the likelihood of producing viable products in a shorter period of time.

Virtual R&D allows Endo to take on multiple development opportunities without investing in in-house facilities and specific capabilities that can be handled by contracting with experts. So Endo has biochemists and other scientists working in our U.S. location, but we use research labs in India and have up to 80 people working there full time under contract, plus dozens more providing support services in their labs. This model saves us development time as well as significant capital costs – it would cost almost 4 times as much to operate an equivalent R&D program entirely in the U.S Read more at medhealth.tmcnet.com

 

See this Amp at http://bit.ly/hl6L9j